Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2011-01-04
2011-01-04
Saoud, Christine J (Department: 1647)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C514S002600, C530S399000, C530S350000
Reexamination Certificate
active
07863246
ABSTRACT:
The present invention relates to the treatment of motoneuron diseases. More particularly, the invention relates to the treatment of amyotrophic lateral sclerosis (ALS). It is found that the intracerebroventricular delivery of low amounts of vascular endothelial growth factor into a pre-clinical ALS animal model induces a significant motor performance and prolongation of survival time of the animals.
REFERENCES:
patent: 5332671 (1994-07-01), Ferrara et al.
patent: 6455283 (2002-09-01), Ferrara et al.
patent: 7125856 (2006-10-01), Isner
patent: 7226908 (2007-06-01), Carmeliet
patent: 7592314 (2009-09-01), Carmeliet
patent: 7687463 (2010-03-01), Carmeliet
patent: 2003/0105018 (2003-06-01), Carmeliet et al.
patent: 2008/0032314 (2008-02-01), Carmeliet
patent: 2008/0279906 (2008-11-01), Carmeliet
patent: WO 98/31395 (1998-07-01), None
patent: WO 99/46364 (1999-09-01), None
patent: WO 99/47677 (1999-09-01), None
patent: WO 00/17371 (2000-03-01), None
patent: WO 00/62798 (2000-10-01), None
patent: WO 01/76620 (2001-10-01), None
Airaksinen et al., The GDNF Family: Signalling, Biological Functions and Therapeutic Value, Nature Reviews Neuroscience, May 2002, pp. 383-394, vol. 3.
Andersen, Peter M., Genetics of sporadic ALS, ALS and other motor neuron disorders 2001, pp. S37-S41, vol. 2, Suppl. 1.
Autiero et al., Role of PIGF in the intra- and intermolecular cross talk between the VEGF receptors Flt1 and Flk1, Nature Medicine, Jul. 2003, pp. 936-943, vol. 9, No. 7.
Azzouz et al., VEGF delivery with retrogradely transported lentivector prolongs survival in a mouse ALS model, Nature, May 27, 2004, pp. 413-417, vol. 429.
Borasio et al., A placebo-controlled trail of insulin-like growth factor-1 in amyotrophic lateral sclerosis, Neurology, Aug. 1998, pp. 583-586, vol. 51.
Boyd et al., A dose-dependent facilitation and inhibition of peripheral nerve regeneration by brain-derived neurotrophic factor, European Journal of Neuroscience, 2002, pp. 613-626, vol. 15.
Cao et al., VEGF links hippocampal activity with neurogenesis, learning and memory, Nature Genetics, Aug. 2004, pp. 827-835, vol. 36, No. 8.
Carmeliet, Angiogenesis in health and disease, Nature Medicine, Jun. 2003, pp. 653-660, vol. 9, No. 6.
Caroni et al., Role of Muscle Insulin-like Growth Factors in Nerve Sprouting: Suppression of Terminal Sprouting in Paralyzed Muscle by IGF-binding Protein 4, The Journal of Cell Biology, 1994, pp. 893-902, vol. 125.
Chen et al., Abstract, Lack of association of VEGF promoter polymorphisms with sporadic ALS, Neurology, 2006, pp. 508-510, vol. 67, No. 3.
Cleveland et al., From Charcot to Lou Gehrig: Deciphering Selective Motor Neuron Death in ALS, Nature Reviews Neuroscience, Nov. 2001, pp. 806-819, vol. 2.
Del Bo et al., Vascular Endothelial Growth Factor Gene Variability is Associated with Increased Risk for AD, Annals of Neurology, Mar. 2005, vol. 57, No. 3.
Ernfors et al., Mice lacking brain-derived neurotrophic factor develop with sensory deficits, Nature, Mar. 10, 1994, pp. 147-150, vol. 368.
Ferrara et al., The biology of VEGF and its receptors, Nature Medicine, Jun. 2003, pp. 669-676, vol. 9, No. 6.
Friedlander, Robert M., M.D., Apoptosis and Caspases in Neurodegenerative Diseases, The New England Journal of Medicine, Apr. 3, 2003, pp. 1365-1375, vol. 348, No. 14.
Giess et al., Early Onset of Severe Familial Amyotrophic Lateral Sclerosis with a SOD-1 Mutation: Potential Impact of CNTF as a Candidate Modifier Gene, Am. J. Hum. Genet., 2002, pp. 1277-1286, vol. 70.
Giess et al., Potential role of LIF as a modifier gene in the pathogenesis of amyotrophic lateral sclerosis, Neurology, Feb. 22, 2000, p. 1003, vol. 54, No. 4.
Greenberg et al., “VEGF and ALS: The luckiest growth factor?” Trends in Molecular Medicine, 2004, pp. 1-3, vol. 10, No. 1.
Gurney, et al., Motor Neuron Degeneration in Mice That Express a Human Cu, Zn Superoxide Dismutase Mutation, Science, Jun. 17, 1994, pp. 1772-1775, vol. 264.
Howland et al., Focal loss of the glutamate transporter EAAT2 in a transgenic rat model of SOD1 mutant-mediated amyotropic lateral sclerosis (ALS), PNAS, Feb. 5, 2002, pp. 1604-1609, vol. 99, No. 3.
Jin et al., Abstract, Vascular Endothelial Growth Factor Rescues HN33 Neural Cells from Death Induced by Serum Withdrawal, Journal of Molecular Neuroscience, 2000, vol. 14.
Jin et al., Vascular endothelial growth factor (VEGF) stimulates neurogenesis in vitro and in vivo, PNAS, Sep. 3, 2002, pp. 11946-11950, vol. 99, No. 18.
Jin et al., Vascular endothelial growth factor: Direct neuroprotective effect in in vitro ischemia, PNAS, Aug. 29, 2000, pp. 10242-10247, vol. 97, No. 18.
Kaspar et al., Retrograde Viral Delivery of IGF-1 Prolongs Survival in a Mouse ALS Model, Science, Aug. 8, 2003, pp. 839-842, vol. 31, No. 5634.
Kilpatrick et al., Abstract, Molecular mechanisms regulating motor neuron development and degeneration, Mol. Neurobiol., Jun. 1999, pp. 205-228, vol. 19, No. 3.
Koh, S. M., Ciliary Neurotrophic Factor Released by Corneal Endothelium Surviving Oxidative Stress Ex Vivo, IOVS, Sep. 2002, pp. 2887-2896, vol. 43, No. 9.
Krum et al., Angiogenic and Astroglial Responses to Vascular Endothelial Growth Factor Administration in Adult Rat Brain, Neuroscience, 2002, pp. 589-604, vol. 110, No. 4.
Kunst et al., Genetic Mapping of a Mouse Modifier Gene That Can Prevent ALS Onset, Genomics, 2000, pp. 181-189, vol. 70.
Lai et al., Effect of recombinant human insulin-like growth factor-I on progression of ALS, Neurology, 1997, pp. 1621-1630, vol. 49.
Lambrechts et al., Abstract, VEGF: necessary to prevent motoneuron degeneration, sufficient to treat ALS? Trends in Molecular Medicine, Jun. 2004, pp. 275-282, vol. 10, No. 6.
Lambrechts et al., VEGF is a modifier of amyotrophic lateral sclerosis in mice and humans and protects motoneurons against ischemic death, Nature Genetics, Aug. 2003, pp. 383-394, vol. 34, No. 4.
Lino et al., Accumulation of SOD1 Mutants in Postnatal Motoneurons Does Not Cause Motoneuron Pathology or Motoneuron Disease, The Journal of Neuroscience, Jun. 15, 2002, pp. 4825-4832, vol. 22, No. 12.
Louissaint et al., Coordinated Interaction of Neurogenesis and Angiogenesis in the Adult Songbird Brain, Neuron, Jun. 13, 2002, pp. 945-960, vol. 34.
Luttun et al., Genetic dissection of tumor angiogenesis: are PIGF and VEGFR-1 novel anti-cancer targets, Biochimica et Biophysica Acta, 2004, pp. 79-94, vol. 1654.
Luttun et al., Revascularization of ischemic tissues by PIGF treatment and inhibition of tumor angiogenesis, arthritis and atherosclerosis by anti-Flt1, Nature Medicine, Aug. 2002, pp. 831-840, vol. 8, No. 8.
Marti et al., Systemic hypoxia changes the organ-specific distribution of vascular endothelial growth factor and its receptors, Proc. Natl. Acad. Sci., Dec. 1998, pp. 15809-15814, vol. 95, USA.
Masu et al., Disruption of the CNTF gene results in motor neuron degeneration, Nature, Sep. 2, 1993, pp. 27-32, vol. 365.
Miller et al., Riluzole for amyotropic lateral sclerosis (ALS)/motor neuron disease (MND), ALS and other motor neuron disorders 2003, pp. 191-206, vol. 4.
Miller et al., Targeted vectors for gene therapy, The FASEB Journal, Feb. 1995, pp. 190-199, vol. 9.
Miller G., Breaking Down Barriers, Science, Aug. 16, 2002, vol. 297, No. 5584.
Moore et al., Renal and neuronal abnormalities in mice lacking GDNF, Nature, Jul. 4, 1996, pp. 76-79, vol. 382.
Nagai et al., Rats Expressing Human Cytosolic Copper-Zinc Superoxide Dismutase Transgenes with Amyotropic Lateral Sclerosis: Associated Mutations Develop Motor Neuron Disease, The Journal of Neuroscience, Dec. 1, 2001, pp. 9246-9254, vol. 21, No. 23.
Ngo et al., Computational Complexity, Protein Structure Prediction, and the Levinthal Paradox, 1994, pp. 491-495.
Nutt et al., Randomized, double-blind trial of glial cell line-derived neurotrophic factor (GDNF) in PD, Neurology, Jan. 2003, pp. 69-73, vol. 60.
Ochs et al., A phase I/II trial of recombinant methionyl human brain derived neurotrophic factor administered by intrathecal infusion to patients with amyotrophic lateral sclerosis, ALS and other motor neuron disorders,
Life Sciences Research Partners VZW
Lockard Jon M
Saoud Christine J
TraskBritt P.C.
Vlaams Interuniversitair Instituut voor Biotechnologie VZW
LandOfFree
Treatment of amyotrophic lateral sclerosis does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Treatment of amyotrophic lateral sclerosis, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Treatment of amyotrophic lateral sclerosis will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2697067